Paraguay approves Medigen vaccine for emergency use | News
The National Directorate of Health Surveillance (Dinavisa) of Paraguay announced this Monday that the vaccine candidate against Covid-19 produced by the Medigen laboratory in Taiwan is admissible to be administered to adults over 18 years of age in the South American country.
Paraguayan Prosecutor’s Office Launches Investigation Against Former President Cartes
According to Dinavisa, the MVC-COV1901 anticovid dose was applied during the three phases of clinical trials in the Paraguayan nation; so its high immunogenicity property and medical safety were proven during the tests.
In this sense, for the clinical tests of the drug against Covid-19, Dinavisa had a sample equivalent to 1,000 national volunteers from Paraguay.
In another order, the health authorities recommend the intramuscular application of two doses of the anticovid vaccine, with an intermediate period of four weeks after the administration of the immunizer.
To date, the vaccination campaign against Covid-19 in Paraguay uses anticovid vaccines, among which are the vaccines from Pfizer and Moderna, Astrazeneca, Sputnik, as well as Coronavac and Sinopharm.